Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 1.00 |
| ▸ | HCRTR2 | O43614 | 15/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198063 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2MTNR1BMTNR1A | |
| SCHEMBL30593432 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2MTNR1BMTNR1A | |
| SCHEMBL27922238 | 0.91 | HCRTR1 (0.84) | HCRTR1HCRTR2MTNR1BMTNR1A | |
| SCHEMBL5206870 | 0.88 | HCRTR1 (0.79) | HCRTR1HCRTR2MTNR1BMTNR1A | |
| SCHEMBL246714 | 0.87 | HCRTR1 (1.00) | HCRTR1HCRTR2MTNR1BMTNR1A | |
| SCHEMBL196581 | 0.87 | HCRTR1 (1.00) | HCRTR1HCRTR2MTNR1BMTNR1A | |
| SCHEMBL196582 | 0.87 | HCRTR1 (1.00) | HCRTR1HCRTR2MTNR1BMTNR1A | |
| SCHEMBL5207553 | 0.87 | HCRTR1 (0.76) | HCRTR1HCRTR2MTNR1BMTNR1A | |
| SCHEMBL5211349 | 0.86 | HCRTR1 (0.76) | HCRTR1HCRTR2MTNR1BMTNR1A | |
| SCHEMBL5210435 | 0.86 | HCRTR1 (0.76) | HCRTR1HCRTR2MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303023-B2 | Pyrazole and imidazole derivatives useful as orexin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-04-05 | — | — | US | disclosed |
| EP-2675801-B1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20130324579-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-05 | — | — | US | disclosed |
| EP-2402322-A1 | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist | Actelion Pharmaceuticals Ltd. (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402322-A1 | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist | Actelion Pharmaceuticals Ltd. (CH) | 2012-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324579-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885MTNR1B 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.